SLC5A2 and Insulin resistance: Sodium-glucose-cotransporter-2 inhibitors (SGLT2-i) reduce insulin resistance, body weight, and blood pressure through increasing urinary glucose secretion in the proximal tubule of the kidney [1] and are also cardioprotective [2].